Biotech M&A, Valuation and Business Development
As an owner-managed advisory boutique, we support Pharma and Biotech companies in navigating complex M&A transactions, business development initiatives and strategic partnerships.
Our Services
M&A and Business
Development Advisory
We advise Pharma and Biotech companies on strategic transformation projects, including:
-
Buy-side and sell-side M&A support, from deal sourcing to closing
-
Identification of target companies, licensing partners and pipeline assets
-
In- and out-licensing strategy and execution
-
Opportunity assessment and due diligence support
-
Deal structuring and negotiation guidance
Valuation & Financial Modeling
We deliver tailored valuation and financial analysis to support strategic decisions:
-
Risk-adjusted Net Present Value (rNPV) valuations of companies and assets
-
Sensitivity analysis to identify key value drivers
-
Scenario modeling to reflect different clinical development outcomes
-
Monte Carlo simulations for probabilistic assessments
Why OCEAN21
We are a boutique advisory – and that is your advantage.
Independent &
execution-oriented:
No standardized processes, no corporate templates. Just individually tailored strategies and full commitment.
Focus on Pharma & Biotech:
We understand the scientific, regulatory, and commercial dynamics of our industry.
C-Level Experience:
We speak the language of investors, founders, and industry partners, and bring them together.
Your Experts
Partner
With over 20 years of experience as an entrepreneur, in business development roles at Big Pharma, and in various commercial positions across listed companies and start-ups, Mischa brings a unique combination of strategic thinking and hands-on industry knowledge. He is passionate about the Pharmaceutical and Biotech industry and offers a strong understanding of its complex business dynamics. At Ocean21, Mischa advises clients on strategy development, partner identification, key transactions, and financial valuation.
Partner
With over 35 years of experience in pharmaceutical business development, Ivan brings deep expertise in licensing, strategic partnering, and deal-making. He held senior roles at Novartis and later advised biotech and pharma companies across Europe. As a strong networker, Ivan is the Co-founder and past president of the Swiss Pharma Licensing Group and a past president of the European Pharma Licensing Council. He has also served on multiple Biotech boards, including as chairman, bringing strategic insight and hands-on governance experience to Ocean21 clients.
Our Network
We have access to an extensive network and can select highly qualified executives with strong track records in deal making to support project management and bring in specialized expertise from other advisors.This includes, for example, deep dives into pricing and market access, legal and financial due diligence, or contract drafting, always tailored to the specific needs of the project.
The company name reflects our philosophy:
Ocean stands for depth and uncertainty, constant movement, and global interconnectivity, just like the Biotech and Pharma industries we work in every day. 21 refers to the 21st century, a time shaped by medical innovation, technological progress, and complex global challenges.
Together, Ocean21 represents our commitment to guiding decision-makers in the life sciences sector through complex transactions and global growth strategies, with entrepreneurial thinking and analytical precision.